Skip to main
REPL

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 57%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group is expected to perform well due to its focus on developing innovative oncolytic immunotherapies for cancer treatment and its proprietary RPx platform based on a novel strain of HSV-1. The company's recent announcement of a different review team for the resubmission of its BLA for RP1 plus nivolumab indicates potential for a positive outcome. With biopsies and surgical interventions showing no impact on tumor response, Replimune's proprietary oncolytic immunotherapy product candidates have the potential to transform the lives of cancer patients.

Bears say

Replimune Group is facing uncertainty after the FDA requested a meeting to discuss concerns about the trial design for its Ph3 IGNYTE-3 study of RP1, with an interim OS readout not expected until 2027. With a decrease in RP1's probability of success, potential cost cutting and a lowered rating from Overweight to Neutral, the company may also need to restructure in order to fund the ongoing trial and/or next-gen RP2 development amid a depleted cash runway.

REPL has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 57% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 7 analysts, REPL has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.